Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Abingdon Health PLC ( (GB:ABDX) ) has issued an announcement.
Abingdon Health PLC has announced significant changes to its Board of Directors, with Chris Yates transitioning from CEO to President of Abingdon Health USA Inc., focusing on US operations and global commercial activities. Dr. Katie Brenner will join as an Independent Non-Executive Director, bringing expertise in lateral flow testing and bioengineering, which is expected to strengthen the company’s capabilities as it expands its focus on the US market and compliance sectors.
More about Abingdon Health PLC
Abingdon Health PLC is a leading med-tech contract service provider that offers a range of services including lateral flow product development, regulatory support, and manufacturing for an international customer base. The company specializes in areas such as infectious disease, clinical testing, and environmental testing, with facilities in York, UK, and Madison, Wisconsin, USA. Abingdon Health also provides regulatory services through its subsidiaries to support the in vitro diagnostic and medical device industries.
YTD Price Performance: -6.45%
Average Trading Volume: 115,903
Technical Sentiment Signal: Buy
Current Market Cap: £14.04M
For detailed information about ABDX stock, go to TipRanks’ Stock Analysis page.